Institut National de la Sante et de la Recherche Medicale, Unité 872, 15 rue de l'Ecole de Médicine, Paris-75006, France.
J Autoimmun. 2012 Sep;39(3):168-72. doi: 10.1016/j.jaut.2012.05.013. Epub 2012 Jun 15.
Intravenous immunoglobulin (IVIg) is a therapeutic preparation consisting of pools of normal, polyspecific IgG antibodies obtained from plasma of several thousand healthy individuals. In addition to its use in primary and secondary immune deficiency, IVIg is increasingly used in the therapy of a large number of autoimmune conditions. Despite its successful use in immunopathologies for over two decades, the precise mechanisms underlying the therapeutic benefit have not been fully elucidated. We and others have demonstrated that IVIg inhibits the antigen uptake and presentation by dendritic cells (DC). Here we report that IVIg-mediated inhibition of uptake and processing of antigens is associated with an increased accumulation of lipid as analyzed by flow cytometry and electron microscopy. As accumulation of lipids in DC is known to impart tolerogenic properties, these findings unravel novel link between antibodies and intracellular physiology of innate cells and may further uncover novel immunoregulatory mechanisms of IVIg in auto-inflammatory diseases.
静脉注射免疫球蛋白(IVIg)是一种治疗制剂,由从数千名健康个体的血浆中获得的正常、多特异性 IgG 抗体组成。除了在原发性和继发性免疫缺陷中的应用外,IVIg 在治疗大量自身免疫性疾病中的应用也越来越多。尽管 IVIg 在免疫病理学中成功应用了二十多年,但治疗效果的确切机制尚未完全阐明。我们和其他人已经证明,IVIg 抑制树突状细胞(DC)对抗原的摄取和呈递。在这里,我们报告说,IVIg 介导的摄取和处理抗原的抑制与通过流式细胞术和电子显微镜分析的脂质积累有关。由于已知 DC 中脂质的积累赋予了耐受原性,这些发现揭示了抗体与先天细胞的细胞内生理学之间的新联系,并可能进一步揭示 IVIg 在自身炎症性疾病中的新型免疫调节机制。